Ventrus Biosciences Inc Stock Nasdaq
Stocks
US9228221019
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 478M 421M 399M 360M 679M 45.86B 688M 4.77B 1.84B 23.44B 1.8B 1.76B 75.16B | P/E 2026 * |
-202x | P/E 2027 * | -8.61x |
|---|---|---|---|---|---|
| Enterprise Value | 392M 345M 327M 295M 556M 37.57B 563M 3.91B 1.51B 19.2B 1.47B 1.44B 61.57B | EV / Sales 2026 * |
6.18x | EV / Sales 2027 * | 10.3x |
| Free-Float |
72.34% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ventrus Biosciences Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Jason Okazaki
CEO | Chief Executive Officer | 50 | 2022-12-31 |
| Director of Finance/CFO | - | 2025-06-04 | |
Katie Kitrinos
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Altig
CHM | Chairman | 70 | 2026-06-03 |
Susan Mahony
BRD | Director/Board Member | 61 | 2017-12-13 |
John McHutchison
BRD | Director/Board Member | 68 | 2019-08-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | -0.36% | +49.37% | +94.17% | 74.46B | |
| -0.71% | +0.72% | +27.12% | +80.04% | 60.14B | |
| -2.43% | -1.19% | +5.35% | +33.94% | 48.15B | |
| -1.60% | -3.14% | +30.71% | +37.39% | 44.25B | |
| +2.13% | +4.57% | +355.71% | +698.59% | 43.99B | |
| -0.75% | +1.77% | +9.31% | +105.24% | 41.61B | |
| -0.67% | +0.17% | +7.60% | +46.37% | 29.97B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 29.31B | |
| -2.49% | -7.12% | -23.35% | +344.99% | 24.93B | |
| Average | +0.32% | +1.53% | +55.40% | +162.61% | 44.09B | |
| Weighted average by Cap. | +0.54% | +1.53% | +59.69% | +153.44% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.43M 55.86M 52.92M 47.78M 90.05M 6.08B 91.21M 633M 244M 3.11B 238M 233M 9.97B | 34.12M 30.05M 28.47M 25.7M 48.44M 3.27B 49.06M 341M 131M 1.67B 128M 125M 5.36B |
| Net income | 1.4M 1.24M 1.17M 1.06M 1.99M 135M 2.02M 14.01M 5.39M 68.78M 5.27M 5.15M 221M | -56.83M -50.05M -47.42M -42.81M -80.68M -5.45B -81.73M -567M -218M -2.79B -213M -209M -8.93B |
| Net Debt | -86.48M -76.16M -72.16M -65.14M -123M -8.29B -124M -863M -332M -4.24B -325M -318M -13.59B | -127M -112M -106M -95.57M -180M -12.17B -182M -1.27B -487M -6.22B -476M -466M -19.94B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
